In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva’s More Convenient Copaxone Puts Payors In A Bind

Executive Summary

Teva Pharmaceutical’s recent launch of a more convenient formulation of its soon-to-be-generic multiple sclerosis blockbuster Copaxone puts payors in a quandary. They must choose whether to position it favorably on formularies, similar to the flexible standing that the original daily injection often enjoys, or restrict access to it in a way that has teeth.

Advertisement

Related Content

Mylan/Natco, Sandoz/Momenta Stew As Teva Cements Copaxone Loyalty
Actavis Deal Brings Generics “DNA” To Primary Care Opportunity, CEOs Say
Copaxone’s Tombstone? 2014 Could Be Year Generic Launches, Momenta Says
Copaxone Reduces Its Dosing Schedule, But Can It Shrink The Competition?
Teva’s Final Copaxone Firewall Is Complexity Of ANDA Review After Court Tosses Patent
Biogen Idec Undercuts Gilenya With $55,000 Yearly Price For Tecfidera

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004180

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel